Introduction:
The prognostic burden of inflammation in chronic kidney disease (CKD) remains poorly characterized, with prior small-scale studies yielding conflicting estimates of the association between elevated C-reactive protein (CRP) and cardio-renal outcomes.
Methods:
We conducted an observational study of...
Katherine R. Tuttle, F. Mazhar, Minjung Han et al.· Circulation· 0 citations
AIMS
To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double-blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D)...
A. Friedman, J. Basile, Robert S. Busch et al.· Diabetes, obesity and metabo...· 0 citations
BACKGROUND AND AIMS
Hypertension is a common attributable cause of chronic kidney disease (CKD). Mineralocorticoid receptor overactivation can lead to hypertension and contributes to CKD progression. In FIND-CKD, finerenone reduced kidney function decline in participants with CKD without diabetes. This prespecified FIN...
H. Heerspink, Jelle M. Beernink, R. Agarwal et al.· European Heart Journal· 0 citations
BACKGROUND AND HYPOTHESIS
The burden and prognostic significance of inflammation in chronic kidney disease (CKD) remains poorly characterized, with prior studies yielding conflicting estimates of the association between elevated high-sensitivity C-reactive protein (hsCRP) and cardio-kidney outcomes.
METHODS
Observati...
F. Mazhar, Minjung Han, Katherine R. Tuttle et al.· Nephrology, Dialysis and Tra...· 0 citations
BACKGROUND AND AIMS
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and kidney outcomes, but their effects on circulating inflammatory biomarkers remain uncertain. We systematically reviewed randomized evidence on the effects of SGLT2is on peripheral-blood inflammatory biomarkers.
METHODS
P...
Mehmet Kanbay, Ermeena Shah, Rama Al-Shiab et al.· Diabetes, obesity and metabo...· 0 citations
Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...
Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al.· Nature Reviews Nephrology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.